{"nctId":"NCT01967225","briefTitle":"Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections","startDateStruct":{"date":"2013-11-23","type":"ACTUAL"},"conditions":["Skin Diseases, Infectious"],"count":125,"armGroups":[{"label":"Tedizolid Phosphate (Sivextro, BAY1192631)","type":"EXPERIMENTAL","interventionNames":["Drug: Tedizolid Phosphate (Sivextro, BAY1192631)"]},{"label":"Linezolid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Linezolid"]}],"interventions":[{"name":"Tedizolid Phosphate (Sivextro, BAY1192631)","otherNames":[]},{"name":"Linezolid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Suspected or confirmed Methicillin-resistant Staphylococcus aureus (MRSA) infection\n* Japanese Male and female patients aged 18 years or above\n* Diagnosis of Skin and soft tissue infection with MRSA either suspected or confirmed as the major cause of infection, with/without SSTI (skin and soft tissue infection)-derived MRSA bacteremia suspected\n\nExclusion Criteria:\n\n* Having received any systemic antibacterial potentially effective against MRSA for \\>/=24 hours within 3 days prior to the first infusion of a study drug, or having received/expected to receive the medication within 24 hours prior to the first infusion, unless antibacterial therapy for \\>/=72 hours proves to be ineffective on or lack appropriate potency (resistant) to MRSA.\n* Moribund clinical condition such as death likely within the first 3 days of a study drug treatment\n* History of significant allergy or intolerance to linezolid or BAY1192631\n* Known or suspected human immunodeficiency virus (HIV) infection with a CD4+ T-cell count \\< 200/Î¼L\n* Chronic treatment with immunosuppressive drugs\n* Active tuberculosis or non-tuberculous mycobacteriosis which need medical treatments\n* Current or anticipated neutropenia with neutrophil count \\< 1,000/ mm\\^3\n* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \\>/= 8 times the upper limit of reference range OR moderate to severe hepatic disease with Child Pugh score \\>/=10.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Response at Test of Cure (TOC)","description":"Clinical response was evaluated by the masked investigator as clinical cure, clinical failure and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null},{"groupId":"OG001","value":"80.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Microbiological Response at Test of Cure (TOC)","description":"Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"90.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at End of Treatment Visit (EOT)","description":"Clinical response was evaluated by the masked investigator as effective, ineffective and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"90.0","spread":null},{"groupId":"OG003","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG003","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiological Response at End of Treatment (EOT)","description":"Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of the Lesion Size From the Screening Visit by Visit (Only Skin and Soft Tissue Infection [SSTI])","description":"Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.05","spread":"96.89"},{"groupId":"OG001","value":"-173.93","spread":"210.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-134.31","spread":"153.3"},{"groupId":"OG001","value":"-317.66","spread":"410.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-174.96","spread":"283.05"},{"groupId":"OG001","value":"-280.69","spread":"386.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-212.63","spread":"369.43"},{"groupId":"OG001","value":"-314.18","spread":"402.93"}]}]}]},{"type":"SECONDARY","title":"Reduction Ratio of the Lesion Size From the Screening Visit to Day 3 to Day 4 Visit (Only Skin and Soft Tissue Infection [SSTI])","description":"Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest. Reduction ratio (%) = 100 \\* (the post baseline value - baseline value) / baseline value. Negative values represent reduction of lesion size compared to baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.32","spread":"40.50"},{"groupId":"OG001","value":"-61.46","spread":"33.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.30","spread":"41.66"},{"groupId":"OG001","value":"-94.61","spread":"6.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.69","spread":"32.40"},{"groupId":"OG001","value":"-90.09","spread":"26.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-81.82","spread":"23.99"},{"groupId":"OG001","value":"-99.09","spread":"2.08"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":83},"commonTop":["Dermatitis contact","Nausea","Injection site pain","Constipation","Diarrhoea"]}}}